| |
Is your lab informatics platform science-aware™️? Many of today's LIMS and ELNs cannot flex without tedious coding or SQL. Read our guide and discover five key markers of a modern lab platform that drives productivity and simplifies life in the lab.
|
|
Today's Big NewsApr 28, 2023 |
| By Gabrielle Masson In a day chock-full of Big Pharma earning calls and accompanying pipeline culls, Amgen is no exception, slicing both of its mid-stage lupus programs for futility. |
|
|
|
By Angus Liu Bristol Myers Squibb is already juggling several important drug launches. But that doesn’t mean the company can’t take on another near-to-market asset now through an M&A deal, CEO Giovanni Caforio said. |
By Conor Hale ResMed has finally been able to scale up production of its sleep apnea hardware and fill the massive gaps left by Philips and its respirator recalls. But now that Philips is looking to make its return, ResMed says it’s off to the races. |
By Zoey Becker As AbbVie trudges through its long-dreaded year of biosimilar erosion to Humira, its longtime CEO is considering giving up the wheel. But such a move would only come after the dust settles, he said. |
|
Thursday, May 4, 2023 | 11am ET / 8am PT Join industry experts for this insightful webinar to learn more about enzyme inhibition studies. We’ll explore how these studies drive informed decisions for drug developers, frequently asked questions from sponsors, recommendations for achieving successful regulatory submission, and more. Register now.
|
|
By Conor Hale After collecting a long-awaited FDA clearance for the latest generation of its wearable continuous glucose monitor last December, Dexcom has offered a peek into the momentum behind its G7 diabetes sensor. |
By Max Bayer Gilead accelerated R&D spending in the first quarter, notching a 25% increase versus the first quarter of 2022. Company executives attributed the rise in part to ramping up a bevy of ongoing mid-to-late-stage trials. |
By Kevin Dunleavy With its next-generation pneumococcal vaccine, Pfizer has been playing catch-up with Merck in the indication’s key age group—infants. Thursday, Pfizer got to the finish line 10 months after its rival, but with a shot that offers more protection. |
By Conor Hale Intuitive Surgical has claimed a new FDA clearance for its single-arm robot, dubbed the da Vinci SP, that expand its reach in urology procedures. |
By Angus Liu The U.S. launch of a biosimilar to AbbVie’s Humira appears to be hurting the copycat’s developer itself. After AbbVie reported a Humira U.S. sales decline of 26% in the first quarter, Amgen said its rival TNF blocker Enbrel suffered an even bigger loss. |
By Max Bayer,Gabrielle Masson Bristol Myers Squibb came in hot with one heck of a news bomb, announcing Thursday that CEO Giovanni Caforio, M.D., plans to retire in November after eight years at the helm. |
By Teresa Carey This week on "The Top Line," we're launching a mini-series on Narcan the nasal spray. It is the first naloxone product to be approved for use without a prescription. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we talk about how Pfizer became the first company in Big Pharma history with $100 billion in sales. We also dive into a J&J data leak, Eli Lilly's manufacturing spending plan and more of this week's top headlines. |
|
|---|
|
|
|
May 1 - 3, 2023 | Jersey City, NJ
Explore In-Depth Discussions Across 3 Tracks Dedicated to Medical Affairs Professionals. Last chance to register! Don’t miss out, register today.
|
|
| ResearchStrategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
| WhitepaperHow can eConsent provide a more flexible approach to informed consent? Sponsored by: YPrime |
| WhitepaperThe preclinical hematotoxicity screening method that helps clients eliminate bad players earlier in the drug development process Sponsored by: ReachBio | The Cell Biology Experts™ |
| WhitepaperWe’ve identified four must-have tools to manage today’s scientific information chaos. How many are you utilizing? Sponsored By: CCC |
| WhitepaperHow advanced medicines commercial readiness differs and the resources needed to maximize potential. Sponsored by: Herspiegel Consulting |
| WhitepaperThis paper outlines an approach that digital health / therapeutics companies can use when developing a go-to-market strategy for the complex US market. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
